Irwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
Back

Psyched Wellness’ Mycological Research Continues To Take Serious Strides Forward

Jan 12, 2021 • 9:08 AM EST
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

In late December, Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) reported to have started to research the impact that muscimol has on a variety of ailments and we are impressed with how the story has advanced since then.

Less than two weeks after Psyched announced that it started to research muscimol, it reported to have commenced a study that is focused on identifying therapeutic values that are associated with muscimol for antioxidant and anti-inflammatory purposes through nerve derived immunity and neuroprotective modulation models.

Creating a Pattern of Execution

We believe these announcements show positive signs that show that Psyched’s management team is focused on driving the story forward and are favorable on this trend. With these two announcements, Psyched is starting to create a track record of execution and we find this to be significant as it relates to the long-term opportunity.

The study on using muscimol for antioxidant and anti-inflammatory purposes will be led by Brian Tancowny and will focus on determining the effectiveness of the active compound muscimol from the Amanita Muscaria mushroom. This study will analyze the potential neuroprotective effects of muscimol through neurotoxicity and immunomodulatory invitro cell-based models and we are following how the study progresses.

If the study indicates that muscimol can have anti-inflammatory properties, it could lead to a more effective natural therapeutic for treating many conditions. We believe the amount of value that is associated with this is unfathomable and will monitor how this aspect of the story advances over the coming months.

The initial study is expected to provide more insight on the potential health and wellness properties that are associated with muscimol that is from the Amanita Muscaria mushroom. We are favorable on the direction the business is heading and believe that this study could provide Psyched with significant upside potential.

A Growth Story to be Aware of

A few weeks ago, Psyched reported a major milestone and shipped the first batch of Amanita Muscaria extract to its contract research organization (CRO) partner to start pre-clinical trials. The goal of the study is to determine the highest dose of the extract that will not cause unacceptable side effects or an overt toxicity in a defined period.

As part of the study, Psyched already sent 108 grams to the CRO’s lab to commence the first phase of its pre-clinical trial. This first batch will be used in a study to determine the maximum tolerated dose (MTD) and we are bullish on this aspect of the story. If Psyched can make it through the pre-clinical trial process, we believe that will add signficant credibility to the operation and this is an opportunity to be aware of.

We believe that Psyched is executing on a multi-faceted growth strategy and are favorable on the risk-reward profile that is associated with it. Going forward, we expect to learn more about these key growth initiatives and believe that the market is discounting the potential value that is associated with it.

Psyched is dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company’s goal is to create a leading brand of premium mushroom-derived products. Psyched is in the process of developing a line of water-based extracts, teas and capsules that are designed to help with three key health objectives: promote stress relief, relaxation and assist with restful sleeping. We consider Psyched to be a differentiated opportunity and are favorable on the direction the management team is bringing the business.

If you are interested in learning more about Psyched Wellness, please send an email to suppport@mushroomstock.com with the subject “Psyched Wellness” to be added to our distribution list.

 

 

 

 

 

 

 

 

 

 

Pursuant to an agreement between StoneBridge Partners LLC and Psyched Wellness Inc. we have been hired for a period of 180 days beginning November 10, 2020 and ending May 10, 2021 to publicly disseminate information about (PSYC) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (PSYC) for or were paid “0” shares of restricted common shares. We own zero shares of (PSYC), which we purchased in the open market. We plan to sell the “ZERO” shares of (PSYC) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (PSYC) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link